Erik Bovinder Ylitalo
Overview
Explore the profile of Erik Bovinder Ylitalo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
424
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Obanda V, Akinyi M, Kingori E, Nyakundi R, Ochola G, Oreng P, et al.
Virus Res
. 2024 Jul;
348:199434.
PMID: 39004284
African Swine Fever (ASF) is caused by a DNA virus (AFSV) maintained and transmitted by the Argasid ticks. The re-emergence of the disease in Africa coupled with its rapid spread...
2.
Rosenbaum W, Ylitalo E, Castel G, Sjodin A, Larsson P, Wigren Bystrom J, et al.
J Clin Virol
. 2024 Apr;
172:105672.
PMID: 38574565
Orthohantaviruses, transmitted primarily by rodents, cause hemorrhagic fever with renal syndrome (HFRS) in Eurasia and hantavirus pulmonary syndrome in the Americas. These viruses, with documented human-to-human transmission, exhibit a wide...
3.
Jaremo H, Semenas J, Bergstrom S, Lundholm M, Thysell E, Widmark A, et al.
Cancers (Basel)
. 2023 May;
15(9).
PMID: 37173903
MicroRNAs (miRNAs) are aberrantly expressed in prostate cancer (PC), but comprehensive knowledge about their levels and function in metastatic PC is lacking. Here, we explored the differential expression of miRNA...
4.
Lundwall A, Ylitalo E, Wikstrom P, Brattsand M
Int J Mol Sci
. 2021 Dec;
22(23).
PMID: 34884832
The human kallikrein-related peptidase 4 (KLK4) and the transcribed pseudogene KLKP1 are reported to be highly expressed in the prostate. When trying to clone transcripts of KLKP1, we partly failed....
5.
Ylitalo E, Thysell E, Landfors M, Brattsand M, Jernberg E, Crnalic S, et al.
Clin Epigenetics
. 2021 Jul;
13(1):133.
PMID: 34193246
Background: Patients with metastatic prostate cancer (PC) are treated with androgen deprivation therapy (ADT) that initially reduces metastasis growth, but after some time lethal castration-resistant PC (CRPC) develops. A better...
6.
Ylitalo E, Thysell E, Thellenberg-Karlsson C, Lundholm M, Widmark A, Bergh A, et al.
Prostate
. 2019 Dec;
80(2):214-224.
PMID: 31799745
Background: Taxane treatment may be a suitable therapeutic option for patients with castration-resistant prostate cancer and high expression of constitutively active androgen receptor variants (AR-Vs). The aim of the study...
7.
Thysell E, Vidman L, Ylitalo E, Jernberg E, Crnalic S, Iglesias-Gato D, et al.
Mol Oncol
. 2019 Jun;
13(8):1763-1777.
PMID: 31162796
Bone metastasis is the lethal end-stage of prostate cancer (PC), but the biology of bone metastases is poorly understood. The overall aim of this study was therefore to explore molecular...
8.
Nordstrand A, Ylitalo E, Thysell E, Jernberg E, Crnalic S, Widmark A, et al.
Int J Mol Sci
. 2018 Apr;
19(4).
PMID: 29670000
Advanced prostate cancer frequently metastasizes to bone and induces a mixed osteoblastic/osteolytic bone response. Standard treatment for metastatic prostate cancer is androgen-deprivation therapy (ADT) that also affects bone biology. Treatment...
9.
Thysell E, Ylitalo E, Jernberg E, Bergh A, Wikstrom P
Cancer Res
. 2017 Dec;
77(24):7131-7132.
PMID: 29212852
No abstract available.
10.
Ylitalo E, Thysell E, Jernberg E, Lundholm M, Crnalic S, Egevad L, et al.
Eur Urol
. 2016 Aug;
71(5):776-787.
PMID: 27497761
Background: Novel therapies for men with castration-resistant prostate cancer (CRPC) are needed, particularly for cancers not driven by androgen receptor (AR) activation. Objectives: To identify molecular subgroups of PC bone...